UBS: Hengrui Medicine's (01276.HK) global business expansion is progressing smoothly. Target price is 87.3 Hong Kong dollars.

date
29/07/2025
Wisdom Financial APP learned that UBS released a research report stating that international cooperation will be the long-term growth driver for Hangzhou Hengrui Medicine (01276.HK), as this transaction proves its research and development capabilities are recognized by international pharmaceutical companies. The company currently has over 90 innovative drugs in clinical trials, making it one of the most comprehensive enterprises in the biopharmaceutical industry in Mainland China. The bank holds a positive view on its innovation and internationalization strategy; with a target price of HK$87.3, it maintains a "buy" rating.